Le Hai, Phan Eileen, Agatstein Lauren, Barber Joshua, Klineberg Eric, Roberto Rolando, Javidan Yashar
8789University of California, Sacramento, CA, USA.
Global Spine J. 2022 Mar;12(2):263-266. doi: 10.1177/2192568220950678. Epub 2020 Aug 28.
Retrospective case series.
To evaluate the variability in opioid prescription following primary single-level lumbar microdiscectomy.
We retrospectively reviewed consecutive patients who underwent primary single-level lumbar microdiscectomy. Only opioid-naïve patients ≥18 years old were included. Patients who had revision microdiscectomy, multilevel decompression, and/or any complication requiring prolonged hospital stay (>2 days) were excluded. The primary outcomes were the maximum daily dosage of opioids prescribed in morphine milligram equivalents (MME) and the number of pills prescribed (equivalent to 5 mg hydrocodone).
Between 2014 and 2019, 169 patients (90 men, 79 women) met inclusion criteria, with a mean age of 46.9 years. Surgery resulted in a statistically significant improvement in VAS (Visual Analogue Scale) score (6.4 to 2.5, < .01). At discharge, 8 patients (4.7%) did not receive any opioid prescription. Of the remaining 161 patients, 1 patient (0.01%) received hydromorphone, 30 (18.6%) Percocet, 43 (26.7%) oxycodone, and 87 Norco (54.0%). The length of opioid prescription was 6.7 days. The maximum daily dosage of opioids prescribed was 70.4 MME (SD 32.1). The total number of pills prescribed was 89.4 (SD 54.7). Twenty-five patients (15.5%) received a refill prescription. Multivariate analysis demonstrated the operating service, prescriber, and hospital admission were statistically significant predictors of maximum daily MME. The prescriber and hospital admission were statistically significant predictors of total number of pills prescribed.
We found significant variability in opioid prescription following primary single-level lumbar microdiscectomy. For standard spinal procedures like lumbar microdiscectomy, opioid-prescribing guidelines should be established to standardize postoperative pain management.
回顾性病例系列研究。
评估初次单节段腰椎显微椎间盘切除术术后阿片类药物处方的变异性。
我们回顾性分析了连续接受初次单节段腰椎显微椎间盘切除术的患者。仅纳入年龄≥18岁且未使用过阿片类药物的患者。排除接受过翻修显微椎间盘切除术、多节段减压术和/或任何需要延长住院时间(>2天)的并发症的患者。主要结局指标为以吗啡毫克当量(MME)表示的阿片类药物每日最大处方剂量以及处方的药片数量(相当于5毫克氢可酮)。
2014年至2019年期间,169例患者(90例男性,79例女性)符合纳入标准,平均年龄为46.9岁。手术使视觉模拟评分(VAS)有统计学意义的改善(从6.4降至2.5,<0.01)。出院时,8例患者(4.7%)未接受任何阿片类药物处方。在其余161例患者中,1例(0.01%)接受了氢吗啡酮,30例(18.6%)接受了羟考酮/对乙酰氨基酚,43例(26.7%)接受了羟考酮,87例(54.0%)接受了诺科(氢可酮/对乙酰氨基酚)。阿片类药物处方时长为6.7天。阿片类药物每日最大处方剂量为70.4 MME(标准差32.1)。处方的药片总数为89.4片(标准差54.7)。25例患者(15.5%)接受了续方。多因素分析显示,手术科室、开方医生和住院情况是每日最大MME的统计学显著预测因素。开方医生和住院情况是处方药片总数的统计学显著预测因素。
我们发现初次单节段腰椎显微椎间盘切除术术后阿片类药物处方存在显著变异性。对于像腰椎显微椎间盘切除术这样的标准脊柱手术,应制定阿片类药物处方指南以规范术后疼痛管理。